Absci to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Absci Corporation (Nasdaq: ABSI) will participate virtually in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 8:30 a.m. Pacific Time. The company specializes in drug and target discovery by leveraging deep learning AI and synthetic biology, aiming to enhance the therapeutic potential of proteins. Absci's Integrated Drug Creation™ Platform allows the identification of novel drug targets and the discovery of optimal biotherapeutic candidates in a streamlined process. For more information, visit www.absci.com.

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Absci’s management is scheduled to present on Tuesday, February 15^th at 8:30 a.m. Pacific Time / 11:30 a.m. Eastern Time. To listen to the live event, please contact your BTIG representative with interest.

About Absci

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com, follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information that we post on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website, or any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact
investors@absci.com

Media Contact
press@absci.com

FAQ

When will Absci Corporation participate in the BTIG MedTech Conference?

Absci Corporation will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 8:30 a.m. Pacific Time.

What is Absci Corporation's focus in the drug discovery field?

Absci Corporation focuses on drug and target discovery using deep learning AI and synthetic biology to enhance the therapeutic potential of proteins.

How does Absci's Integrated Drug Creation™ Platform work?

Absci's Integrated Drug Creation™ Platform identifies novel drug targets, discovers optimal biotherapeutic candidates, and generates manufacturing cell lines in a single efficient process.

Where can I find more information about Absci Corporation?

More information about Absci Corporation can be found on their website at www.absci.com.

What is the stock symbol for Absci Corporation?

The stock symbol for Absci Corporation is ABSI.